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Wiskott-Aldrich syndrome is a severe X-linked recessive immunedeficiency disorder. A scoring system of Wiskott-Aldrich syn-drome severity (0.5-5) distinguishes two phenotypes: X-linked
thrombocytopenia and classic Wiskott-Aldrich syndrome. Hematopoietic
cell transplantation is curative for Wiskott-Aldrich syndrome; however, the
use of unrelated umbilical cord blood transplantation has seldom been
described. We analyzed umbilical cord blood transplantation outcomes for
90 patients. The median age at umbilical cord blood transplantation was 1.5
years.  Patients were classified according to clinical scores [2 (23%), 3 (30%),
4 (23%) and 5 (19%)]. Most patients underwent HLA-mismatched umbili-
cal cord blood transplantation and myeloablative conditioning with anti-
thymocyte globulin. The cumulative incidence of neutrophil recovery at
day 60 was 89% and that of grade II-IV acute graft-versus-host disease at
day 100 was 38%. The use of methotrexate for graft-versus-host disease
prophylaxis delayed engraftment (P=0.02), but decreased acute graft-versus-
host disease (P=0.03). At 5 years, overall survival and event-free survival
rates were 75% and 70%, respectively. The estimated 5-year event-free sur-
vival rates were 83%, 73% and 55% for patients with a clinical score of 2,
4-5 and 3, respectively. In multivariate analysis, age <2 years at the time of
the umbilical cord blood transplant and a clinical phenotype of X-linked
thrombocytopenia were associated with improved event-free survival.
Overall survival tended to be better in patients transplanted after 2007
(P=0.09). In conclusion, umbilical cord blood transplantation is a good alter-
native option for young children with Wiskott-Aldrich syndrome lacking an
HLA identical stem cell donor.
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ABSTRACT
Introduction 
Wiskott-Aldrich syndrome (WAS) is a severe X-linked
recessive immune deficiency disorder caused by muta-
tions in the gene encoding for Wiskott-Aldrich syndrome
protein (WASP), a key regulator of actin polymerization
signaling and cytoskeletal reorganization in hematopoietic
cells.1-3 A mutation in WASP results in a broad spectrum of
clinical manifestations ranging from the relatively mild X-
linked thrombocytopenia (XLT) to the classic WAS pheno-
type characterized by microthrombocytopenia, immun-
odeficiency, eczema, and high susceptibility to lympho-
proliferative tumors and autoimmune diseases.2,4,5 A sim-
ple scoring system on a scale from 0.5 to 5 was introduced
to differentiate XLT from classic WAS patients based on
the severity of the clinical phenotype (Online
Supplementary Table S1).6
XLT patients (score <3) have excellent overall survival
(OS), but also have a high probability of severe disease-
related complications.7 In contrast, the classic WAS (score
≥3) usually leads to death in early childhood or adoles-
cence, despite advances in clinical care, with a median life
expectancy of only 15 years.6,8,9 
Currently, the only proven curative therapy for patients
with WAS is hematopoietic stem cell transplantation
(HSCT).6,10 Various series of HSCT from HLA-matched
related donors have consistently resulted in survival rates
above 80% for patients with WAS.11-15 In the absence of a
matched related donor, the OS reported after matched
unrelated HSCT has been around 70%.11 In the last 20
years, unrelated donor umbilical cord blood transplanta-
tion (UCBT) has become an option for patients lacking an
HLA-matched donor.16 To date, there are only few reports
on outcomes after UCBT for patients with primary
immune deficiencies,17-19 and they include only a few
patients with WAS;18,20-22 furthermore, none of the studies
has analyzed factors associated with outcomes after
UCBT. We, therefore, conducted a collaborative, multi-
center, retrospective risk factor analysis of patients with
WAS reported to Eurocord. A total of 90 UCBT recipients
met the criteria and were included in the study. 
Methods
Data collection
This retrospective analysis is based on data reported to the
European Blood and Marrow Transplantation group (EBMT)
and/or Eurocord from European and non-European transplant cen-
ters through a standardized questionnaire that included informa-
tion on patients, donors, diseases, and transplant outcomes.
Missing information was requested in the form of a Microsoft
Excel file listing transplants performed by each center along with
key data extracted from the Eurocord-EBMT databases. In addi-
tion, data from Duke University Medical Center (USA), the
Federal University of Parana (Brazil) and the Pontifical Catholic
University of Chile were obtained from the respective centers.
Recipients’ parents or legal guardians gave informed consent for
HSCT according to the Declaration of Helsinki. Eurocord and the
Working Party of Inborn Errors of the EBMT approved this study.
Inclusion criteria
The inclusion criteria for the study were: (i) patients transplant-
ed for WAS before December 31, 2013, and reported to Eurocord;
(ii) first allogeneic unrelated HSCT. 
Patients were excluded from the study if the diagnosis of
immune deficiency was not specified or if transplants were per-
formed with a cord blood unit that was expanded, combined
with other sources of hematopoietic stem cells, or injected intra-
bone.
Endpoints and definitions 
The primary endpoint was: event-free survival (EFS), defined as
survival from transplantation to last contact without any of the
following events: autologous reconstitution (defined by documen-
tation of <5% donor-derived engraftment), graft failure (defined as
a lack of neutrophil recovery or transient engraftment of donor
cells after transplantation, and/or a requirement for a second trans-
plant) and death. All surviving patients were censored at the date
of last contact. 
Other endpoints reported included: (i) OS, defined as the time
from transplantation to death from any cause; (ii) cumulative inci-
dence of neutrophil engraftment, defined as the first day of achiev-
ing a neutrophil count of ≥0.5x109/L for 3 consecutive days with
evidence of donor hematopoiesis; (iii) cumulative incidence of
platelet engraftment, defined as the first of 3 consecutive days
after HSCT with a platelet count ≥20x109/L without platelet trans-
fusions for at least 7 days; (iv) graft failure: primary failure defined
as the neutrophil count never reaching 0.5x109/L or evidence of
autologous reconstitution; secondary graft failure defined as reach-
ing a neutrophil count of 0.5x109/L after transplantation, but expe-
riencing a subsequent, non-transitory, decrease, or loss of donor
chimerism; and (v) the incidence of acute and chronic graft-versus-
host disease (GvHD). Acute GvHD grade II-IV was diagnosed and
graded according to published criteria.23 Chronic GvHD was also
graded according to standard criteria24 and evaluated in patients
who survived at least 100 days with sustained engraftment.
Myeloablative conditioning was defined as conditioning includ-
ing an intravenous busulfan total dose of more than 6.4 mg/kg or
an oral dose greater than 8 mg/kg/day, or treosulfan >36 mg/m2 for
infants (less than 12 months old) and >42 mg/m2 for others. Other
regimens were considered reduced intensity conditioning. 
Donor-recipient HLA matching was defined considering low
resolution typing for HLA class I (A and B) and high resolution typ-
ing for HLA class II (DRB1). Donor-recipient chimerism was
reported on the basis of available data during the first 100 ± 30
days, 1 year ± 30 days after UCBT and at the last chimerism eval-
uation. Full donor chimerism was defined as the presence of ≥95%
donor-derived hematopoietic cells, mixed-chimerism as 5% to
94% of these cells and autologous recovery if <5%. 
The patients’ immunophenotype (CD3+CD4+ and CD3+CD8+ T-
lymphocytes; CD19+ B-lymphocytes) was determined 100 ± 30
days, 1 year ± 30 days and at the last assessment reported after
UCBT.  As normal values in childhood vary considerably with age,
absolute numbers of CD4+, CD8+ and CD19+ cells were related to
age-specific normal values.25,26 Immune recovery was defined as
being alive with neutrophil engraftment and achieving absolute
numbers of CD4+, CD8+ and CD19+ cells within the age-related
normal values, as shown in Online Supplementary Table S2.
Statistical analysis
To analyze risk factors for outcomes, we considered factors
related to the patient (median age at diagnosis, median age at
transplant, median weight at time of transplantation, gender, pre-
transplant cytomegalovirus serology status, Lansky score), disease
[pre-transplant information on: infections, severe thrombocytope-
nia (platelets <20x109/L), number of platelet transfusions, platelet
abnormalities, history of severe bleeding, splenectomy, presence
of eczema, autoimmunity, malignancy, congenital neutropenia,
clinical phenotype, median interval from date of birth to diagnosis,
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median interval from diagnosis to transplant], cord blood unit
(HLA matching, median numbers of total nucleated cells and
CD34+ cells collected and infused), and the transplant (year of
transplantation, use of reduced intensity or myeloablative condi-
tioning, type of GvHD prophylaxis).  
Cumulative incidence curves were calculated for neutrophil and
platelet engraftment, and acute and chronic GvHD in a competing
risk setting, with death as a competing event.27 Gray test was used
for univariate comparisons. Probabilities of EFS and OS were cal-
culated using the Kaplan-Meier estimate; the two-sided log-rank
test was used for univariate comparisons. Multivariate analyses
were performed using the Cox proportional hazard regression
model28 for EFS and OS, and the proportional sub-distribution haz-
ard regression model of Fine and Gray for acute and chronic
GvHD, and neutrophil and platelet engraftment. Variables that
reached a P-value of 0.10 in the univariate analysis, and other rel-
evant factors such as HLA matching and cell dose, were included
in the initial models and variables were eliminated one by one in
a stepwise fashion in order to retain only those variables that
reached a P-value of 0.05 in the final model. P-values were two-
sided. Statistical analyses were performed using SPSS (Inc.,
Chicago, IL, USA) and S-Plus (MathSoft, Inc., Seattle, WA, USA)
software packages. 
Results
Characteristics of the patients, donors and transplants
Ninety patients with a clinical diagnosis of WAS who
underwent UCBT between 1996 and 2013 in 33 centers
from 20 countries met the eligibility criteria for the study.
The baseline characteristics of the patients, donors and
transplants are shown in Table 1. Disease severity before
transplantation was expressed as a WAS score of 2 to 5.
Eighteen patients (23%) had a WAS clinical score of less
than 3 at the time of UCBT, indicating that they had not
experienced any of the following: severe infections, diffi-
cult-to-treat eczema, autoimmunity, or malignancy. The
majority of patients (n= 61, 77%) had severe clinical fea-
tures of the disease at the time of transplantation, includ-
ing 52 patients with a history of recurrent and/or severe
infections. Seven patients had a history of autoimmune
disorders and two had  a history of Epstein-Barr virus-
associated lymphoproliferative disease. 
Four patients were splenectomized before UCBT, of
whom two had a platelet count <20x109/L at the time of
transplantation. All of the splenectomized patients had the
classic WAS clinical phenotype and three experienced
severe infection before UCBT.
Data on WAS gene mutations were available for 39
patients (43%). Almost equal proportions of patients car-
ried nonsense, missense and deletion mutations. 
The median age at transplantaion was 1.48 years (range,
4.8 months – 14.25 years).  Only nine patients were more
than 5 years old at the time of UCBT. Most patients (76%)
had a good performance status at the time of UCBT
(Lansky score >80%).
The vast majority of children were conditioned with a
busulfan-containing myeloablative regimen (97%), mainly
busulfan/cyclophosphamide (76%). Three patients received
reduced-intensity conditioning, two of them due to severe
infection at the time of UCBT. Most patients received anti-
thymocyte globulin (n=79). All patients who received
GvHD prophylaxis received a calcineurin inhibitor-contain-
ing regimen, including either cyclosporine A (in most cases)
Z. Shekhovtsova et al.
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Table 1. Baseline characteristics of the patients, disease, donors and trans-
plants.
                                                                          N =90 (%*)         Median (range)
Patients’ characteristics                                                                                            
Gender (male/female)                                                      88/2                                 
Weight, kg                                                                     10.25 (5-51.7)
Age at diagnosis, years                                                                                     0.32 (0-8.3)
Time interval diagnosis- UCBT, years                                                      1.05 (0.06-13.05)
Age at transplantation, n.                                                                            1.48 (0.40-14.25)
≤5 years                                                                                81
> 5 years                                                                               9
CMV status before UCBT, n (%)                                          
Seropositive                                                                     47(70)
Seronegative                                                                   20 (30)
Disease characteristics, n (%)
WAS clinical phenotype at UCBT
Severe infections                                                           52 (68)
Eczema                                                                                    
Mild                                                                               19 (28)
Moderate                                                                     35 (51)
Severe                                                                          14 (21)
Severe thrombocytopenia (<20x109cells/L)            43 (70)
Microthrombocytopenia                                               22 (51)
Life-threatening bleeding                                            41 (59)
Malignancies                                                                     2 (4)
Autoimmunity                                                                   7 (13)
Congenital neutropenia                                                 9 (19)
WAS score  
2                                                                                     18 (23)
3                                                                                     24 (30)
4                                                                                     18 (23)
5                                                                                     19 (24)
Splenectomy before UCBT                                            4 (5)
Donors’ characteristics, n (%)
HLA-matching
6/6                                                                                 11 (12)
5/6                                                                                 52 (58)
4/6                                                                                 25 (28)
3/6                                                                                       1
Cell dose       
Collected NC (x107/kg)                                                                                   7.5 (0.2-3)
Collected CD34+ (x105/kg)                                                                          3.03 (0.03-35)
Transplant characteristics                                                    
Year of transplantation                                                                               2007 (1996-2013)
Conditioning regimen                                                            
Myeloablative                                                                    87 (97)
Cy/Bu                                                                                      67
Cy/Bu+others                                                                       8
Bu/Fluda                                                                                 6
Fluda/Treo  42                                                                       5
Cy/Hydroxyurea                                                                    1
Reduced intensity                                                                  3
Cy/Bu                                                                                       1
Fluda/Melph ± Treo 36                                                     1/1
GvHD prophylaxis                                                                    
CNI/prednisolone                                                          49 (54)
CNI/methotrexate                                                                                               17 (20)
CNI/mycophenolate mofetil                                                                             11 (12)
CNI                                                                                      9 (10)
CNI/others                                                                         3 (3)
Not given                                                                            1 (1)
Serotherapy                                                                              
Anti-T serotherapy (before day 0)                             79 (89)
Monoclonal antibody                                                       2 (2)
Not given                                                                            8 (9)
*Percentage of evaluable cases. UCBT: umbilical cord blood transplantation; CMV:
cytomegalovirus; WAS: Wiskott-Aldrich syndrome; NC: nucleated cells; MAC: myeloablative con-
ditioning regiment; Cy,: cyclophosphamide; Bu: busulphan; Fluda: fludarabine; Treo: treosul-
phan; GvHD: graft-versus-host disease; CNI: calcineurin inhibitor.
or tacrolimus. The median numbers of total nucleated cells
and CD34+ cells infused were 6.8x107 cells/kg and
3.04x105/kg (pre-cryopreservation counts), respectively.
Neutrophil and platelet recovery
Eighty patients (89%) achieved neutrophil engraftment,
with a median time to engraftment of 21 days (range, 9-54).
The cumulative incidence of neutrophil engraftment was
70% and 89% at days 30 and 60, respectively. Ten (11%)
patients did not achieve neutrophil engraftment. Of the
patients who failed to engraft, four received a second trans-
plant and were alive at last follow-up; six did not receive a
second HSCT and died.
Multivariate analysis showed that use of methotrexate in
GvHD prophylaxis [hazard ratio (HR)=0.55, 95% confi-
dence interval (95% CI): 0.32-0.93; P=0.02)] was associated
with a lower cumulative incidence of neutrophil engraft-
ment. 
At day 180, the cumulative incidence of platelet engraft-
ment was 75%, with a median time to engraftment of 45
days (range, 11-224). Platelet engraftment in the four
splenectomized patients seemed faster, occurring at a medi-
an time of 35 days. Due to the small number of splenec-
tomized patients, it was not possible to confirm whether
this procedure has a real impact on the engraftment rate. In
univariate analysis, the only risk factor associated with a
lower cumulative incidence of platelet engraftment was age
more than 2 years (67% versus 79% for younger patients,
P=0.03). Multivariate analysis confirmed that age was inde-
pendently associated with platelet engraftment (HR=0.34,
95% CI: 0.16-0.73; P=0.005). 
Chimerism and immune recovery
Chimerism data were available for 66 (86%) out of 77
evaluable patients at 100 (±30) days after UCBT, 50 (80%)
out of 63 patients at 1 year (±30 days) after UCBT, and 51
(82%) out of 62 patients at the last assessment. At day
100, 68% of patients had full donor chimerism and 32%
had mixed chimerism; at 1 year, these values were 76%
and 24%, respectively while at the last assessment they
were 80% and 20%, respectively. In 12 cases, mixed
chimerism became full donor reconstitution in a further
assessment, and two patients who, initially, had full donor
reconstitution became stable mixed chimera at their last
assessment. 
Information on the absolute number of CD3+/4+,
CD3+/8+ and CD19+ lymphocytes at 100 ± 30 days, 1 year
± 30 days and at the latest assessment after UCBT was
available for 29, 25 and 25 of the patients who were alive
with neutrophil engraftment at the specific time-points,
respectively.  In this subset analysis, 31 (67%) out of 46
patients achieved immune recovery. The median time
between UCBT and the first reported immune recovery
testing was 12 months; 11 patients achieved immune
recovery within the first 12 months after transplantation;
the earliest confirmed immune recovery was reported 4
months after UCBT. Fifteen patients did not achieve
immune recovery. Of these, 13 patients were being treated
with immunosuppressive agents due to acute GvHD; the
remaining two patients, who had no history of GvHD,
had mixed chimerism results. 
Acute and chronic graft-versus-host disease
Acute GvHD grade II-IV was observed in 35 patients: 22
had grade II (24%), 8 had grade III (8%), and 5 had grade
IV (6%). The cumulative incidence of acute GvHD grade
II-IV at day 100 was 38%. In univariate analysis, none of
the factors analyzed was significantly associated with an
increased risk of grade II-IV GvHD. However, in multivari-
ate analysis, the use of methotrexate for GvHD prophy-
laxis was associated with a decreased incidence of grade
II-IV GvHD (22% versus 42%) (HR=0.34, CI 95%: 0.12-
0.91; P=0.03). The cumulative incidence of chronic GvHD
at 5 years was 17% (n=15; 6 extensive and 9 limited
cases). In univariate analysis, the cumulative incidence of
chronic GvHD decreased after 2007 (25% versus 3%,
P<0.01). Chronic GvHD also decreased for patients receiv-
ing a total nucleated cell dose lower than 6.8x107/kg, (23%
versus 7%, P=0.03). In multivariate analysis, none of the
risk factors studied was significantly associated with an
increased risk of chronic GvHD.
Overall survival, event-free survival and causes 
of death 
The probabilities of OS and EFS at 5 years were 75±5%
and 70±5%, respectively. Table 2 shows the univariate
analysis of risk factors for OS and EFS. The risk factors
associated with worst OS in multivariate analysis (Table 3)
were: age over 2 years at UCBT (HR=2.61, 95% CI: 1.1-
6.16; P=0.02) and clinical score >2 (HR=4.49, 95% CI:
1.02-19.78; P=0.04)] (Figures 1 and 2). There was a trend
to improved OS in patients transplanted after 2007
(HR=2.27, 95% CI: 0.86-5.98; P=0.09) (Figure 3). In multi-
variate analysis for EFS, older children (more than 2 years)
at UCBT also had a significantly worse prognosis
(HR=2.47, 95% CI: 1.1-5.52; P=0.02)]. Sixty-seven patients
were alive at the last assessment, with a median follow-up
of 5 years (range, 0.25-17). Twenty-three (25%) patients
had died. Table 4 shows causes of death less than and
more than 100 days after UCBT, according to WAS score.
Infection-related deaths were commonly observed among
patients with all disease scores, and infection was the
main cause of death, especially before day 100.
Discussion 
This multicenter, retrospective study on UCBT recipi-
ents with WAS confirms that, for most patients, HSCT
using HLA-matched or -mismatched cord blood cells can
cure and prevent the long-term, life-threatening complica-
tions associated with WAS.  Outcomes of patients with
WAS who do not undergo HSCT remain poor, with the
mean age at death being 20 years in previous reports9 and
with increasing risk of malignancies with age. Several
groups11,15,16 reported successful HSCT results  with an OS
of up to 88% when using a “gold standard donor”.14 In the
absence of a matched related donor, other groups have
reported the successful use of matched unrelated donors
with 71% OS.11,29,30 but with higher risks of acute and
chronic GvHD. Unfortunately, many patients do not have
an available matched unrelated donor and, therefore,
other donor sources for transplantation have been investi-
gated, such as T-cell-depleted haploidentical HSCT and
umbilical cord blood HSCT. The results after haploidenti-
cal HSCT with TcRαβ/CD19-depletion for patients with
primary immunodeficiency currently seem promising.31
On the other hand, UCBT is still attractive because of the
naïvety of the stem cells, the lower HLA matching require-
ments, and easy availability (compared to matched related
UCBT for Wiskott-Aldrich syndrome
haematologica | 2017; 102(6) 1115
and matched unrelated donors) and decreased GvHD
(compared to haploidentical HSCT).32
We conducted this risk factor analysis for WAS, a rare
disease, using retrospective-registry-based data. The limi-
tations of our study are mainly due to some missing data
related to the disease and the long inclusion period with
changes in cord blood unit selection and better supportive
care in more recent years. Despite these limitations, the
study remains noteworthy, as it is the largest series of chil-
dren with WAS treated with UCBT. 
We were able to identify two main factors associated
with EFS and OS after UCBT: age at UCBT and clinical
disease score (Figures 1 and 2).  EFS and OS were signifi-
cantly improved when transplantation was performed
before 2 years of age, with almost 80% of these young
patients being cured. This finding supports the need for
early referral for transplantation in infants diagnosed with
WAS. We could speculate that older children could have
more previous complications before UCBT, which, in
turn, could affect outcomes. However, in patients with
available data, we determined that OS and EFS were not
associated with number of previous infections, Lansky
score, severity of eczema, thrombocytopenia, number of
previous platelet transfusions, autoimmunity or congenital
neutropenia. 
Clinical score was also a prognostic factor. As expected,
patients with XLT (score <3) had better OS and EFS than
patients with other clinical phenotypes. XLT patients
have, historically, excellent OS without transplantation in
contrast to patients with classic WAS. However, EFS in
XLT patients seems to worsen over time.33,34 Data from the
XLT registry showed an EFS of 74% at 15 years, decreas-
ing to 56% by 30 years, without subsequent transplanta-
tion. There is currently no consensus on the indications for
HSCT in XLT and the decision regarding transplantation
for such patients has to be made on an individual basis.7 In
our cohort, 23% of the patients were classified as having
score 2, and there were no patients with a score of 0.5 or
1 (Table 1), showing that some degree of severity was
present to justify the transplantation. We found that
patients with a clinical score of 3 seemed to have worse
OS and EFS probabilities, although we were not able to
draw definitive conclusions because of the small number
of patients in the groups.
The most frequent cause of death after UCBT was infec-
tion. The majority of patients in our series received anti-
thymocyte globulin as part of their conditioning regimen,
which may explain the high number of infection-related
deaths observed.35 Infections are commonly seen after
UCBT due to delayed engraftment and impaired immune
recovery mainly when anti-thymocyte globulin is used
before UCBT.36
We were able to analyze immune recovery in a subset
of patients. We found that 67% of the 46 patients with
available information achieved immune recovery. The
median time between UCBT and the first test reporting
immune recovery was 12 months, and 11 patients
achieved immune recovery within 12 months of trans-
plantation. These results seem comparable to those
regarding immune recovery usually observed after
UCBT.26 However, due to the retrospective nature of our
analysis, we were unable to collect details on intravenous
immunoglobulin use or vaccine-specific antibody respons-
es; the immune recovery results reported here should,
therefore, be taken with caution. Most patients who did
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Table 2. Probability of 5-year overall and event-free survival after umbilical cord
blood transplantation for Wiskott-Aldrich syndrome.
5 years OS  % 5 years EFS  % 
(95%CI) (95%CI)
Variable N P P
Patients’ characteristics
Age at UCBT
≤ 2 years 60 83 (71-91) 0.027 78 (67-86) 0.05
> 2 years 30 58 (41-74) 55 (38-71)
CMV status
negative 19 77 (54-91) 0.9 73 (51-88) 0.9
positive 47 80 (66-89) 74 (59-85)
Weight at UCBT
<10 kg 45 89 (76-96) 0.002 82 (68-91) 0.02
≥ 10 kg 45 60 (44-74) 58 (42-72)
Splenectomy
Yes 4 50 (15-85) 0.2 50 (15-85) 0.33
No 75 76 (42-93) 72 (61-81)
Lansky score
<90% 19 67 (44-84) 0.63 57 (34-77) 0.2
≥ 90% 59 76 (63-86) 74 (61-84)
Disease characteristics
Clinical score
2 18 89 (69-97) 0.03 83 (61-94) 0.18
3 24 61 (41-77) 55 (35-75)
4 18 78 (55-91) 72 (50-88)
5 19 79 (57-91) 74 (52-88)
UCBT characteristics
HLA-match
6/6 11 71 (41-90) 0.9 61 (33-83) 0.75
5/6 53 76 (63-86) 72 (59-82)
4/6 or 3/6 26 72 (52-86) 69 (50-83)
ABO-compatibility
no incompatibility 36 70 (47-86) 0.8 72 (55-850 0.9
minor  incompatibility 17 76 (58-88) 70 (47-86)
major  incompatibility 29 70 (49-85) 70 (51-84)
Year of UCBT
before 2007 51 69 (54-81) 0.13 65 (51-77) 0.2
after 2007 39 83 (66-93) 78 (62-51)
Time from diagnosis to UCBT
< 7 months 23 91 (73-97) 0.14 86 (68-95) 0.18
7-13 months 22 80 (56-93) 76 (53-90)
>13-19 months 22 72 (50-87) 68 (47-83)
> 19 months 22 58 (37-77) 54 (34-73)
Conditioning regimen
Cy/Bu/ATG 25 83 (64-93) 0.2 83 (60-91) 0.3
others 65 72 (60-81) 67 (55-77)
GvHD prophylaxis
methotrexate 18 74 (63-83) 0.7 70 (57-80) 0.7
others 72 78 (54-91) 72 (48-88)
Cell doses
TNC collected
< 7x107/kg 43 72 (57-83) 0.43 67 (52-79) 0.4
≥ 7x107/kg 42 77 (61-88) 73 (58-84)
TNC infused
< 6x106/kg 43 77 (61-88) 0.8 74 (59-85) 0.5
≥ 6x106/kg 42 72 (57-83) 65 (49-79)
CD34+collected
< 3x106/kg 34 68 (51-81) 0.2 62 (46-76) 0.12
≥  3x106/kg 33 78 (59-90) 75 (57-87)
CD34+ infused
<3x105/kg 34 66 (52-78) 0.11 74 (59-85) 0.14
≥3x105/kg 33 86 (64-95) 75 (57-87)
UCBT: umbilical cord blood transplantation; OS: overall survival; EFS: event-free survival; CI: con-
fidence interval; CMV,: cytomegalovirus; Cy: cyclophosphamide; Bu: busulphan; ATG: anti-thymo-
cyte globulin; GvHD: graft-versus-host disease; TNC: total nucleated cells.
not achieve immune recovery were treated with immuno-
suppressive agents due to acute GvHD, which may
explain our findings. 
Mixed chimerism is an undesirable outcome following
HSCT for WAS since it may be associated with lym-
phopenia, autoimmunity and thrombocytopenia.16 In our
series, chimerism data were available for 86% of the
patients at 3 months, 12 months and the last assessment.
Full donor chimerism was observed in 68%, 76% and
80% of the patients at these timepoints, respectively. In a
recent study of chimerism in 194 HSCT recipients with
WAS, 72.1% of patients achieved full and stable donor
chimerism.16 In this study it was also shown that mixed
chimerism affects the myeloid compartment (16.5% of
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Table 3. Multivariate analysis for overall survival and event-free survival.
HR 95% CI P
Overall survival
Older than 2 years 4.49 1.02-19.78 0.04
WAS score more than 2 2.61 1.1-6.16 0.02
UCBT after 2007 2.27 0.86-5.98 0.09
Event-free survival
Older than 2 years 2.47 1.1-5.52 0.02
WAS score more than 2 3.13 0.9-10.87 0.07
UCBT after 2007 1.68 0.7-4.04 0.24
HR,: hazard ratio; CI: confidence interval; WAS,: Wiskott-Aldrich syndrome; UCBT:
umbilical cord blood transplantation.
Figure 1. Probability of overall survival after
umbilical cord blood transplantation for
Wiskott-Aldrich syndrome according to age. 
Figure 2. Probability of event-free survival
after umbilical cord blood transplantation
for Wiskott-Aldrich syndrome according to
clinical score.  
cases), followed by the B-cell compartment (7.4% of
cases) and uncommonly the T-cell compartment (3.2% of
cases). Unfortunately, in our series, we did not have data
on lineage-specific chimerism; however, our results are
comparable with the 72% full donor chimerism seen with
other sources of hematopietic stem cells.
We were unable to identify cord blood donor-related
factors associated with outcomes. Previously, the
Eurocord group reported that for UCBT recipients with
non-malignant disorders, a cell dose higher than 5x107/kg
and 6/6 or 5/6 HLA-matched grafts are associated with
decreased mortality.35 In our study, patients were trans-
planted with a median cell dose of 7.5x107/kg and 70%
received a 6/6 or 5/6 matched cord blood graft, which is in
agreement with the recommendations for cord blood
selection for patients with non-malignant disorders. 
In conclusion, early referral for UCBT in patients with
WAS is associated with better outcomes. New treatment
strategies such as autologous gene-modified HSCT may
overcome the disadvantages of graft rejection and GvHD
after allogeneic HSCT. However, until these strategies
become clinically available, UCBT remains a good alterna-
tive for patients lacking an HLA-matched donor. 
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